SecurityAMD / Advanced Micro Devices, Inc. (007903107)
Latest Market Date2018-07-13
Short Volume11,033,837
Market Volume 81,396,800
Short Percent 14%

Short Interest and Volume

AMD / Advanced Micro Devices, Inc. Short Interest

AMD / Advanced Micro Devices, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.

Short Volume
Total number of short shares traded on the major US markets each day
Short Percent
Total number of short shares traded divided by the total shares traded each day
Short Interest
Total number of open short positions of a security, divided by the total float (not shown)
Short Squeeze
When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.

Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.

Market Date Total Volume Short Volume Short Percent
2018-07-13 81,396,800 11,033,837 13.56
2018-07-12 88,376,200 11,667,078 13.20
2018-07-11 85,088,200 11,800,813 13.87
2018-07-10 74,185,800 11,208,519 15.11
2018-07-09 117,051,000 16,281,553 13.91
2018-07-06 130,203,200 12,927,199 9.93
2018-07-05 81,406,400 8,984,289 11.04
2018-07-03 64,188,000 8,280,484 12.90
2018-07-02 86,797,400 11,602,533 13.37
2018-06-29 83,055,400 11,991,678 14.44
AMD: Advanced Micro Devices Stock Analysis and Research Report

2017-09-28 - Asif

We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

7h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 007903107